Epilepsy Drug ‘Cenobamate’ Nears Korea Launch…Dong-A ST applies for approval
The domestic introduction of SK Biopharmaceuticals’ epilepsy drug ‘Cenobamate’ (marketed as ‘Xcopri’ in the U.S.) is underway. Cenobamate,…
SK Biopharmaceuticals
3 개의 기사가 있습니다.
Cenobamate Proven Effective for Patients in Korea, China, and Japan
SK Biopharmaceuticals announced that its anti-epileptic drug Cenobamate has demonstrated clinical efficacy for patients in Northeast Asia, paving…
SK Biopharmaceuticals Aims to Become a Global RPT Leader by 2027
SK Biopharmaceuticals has set an ambitious goal to emerge as a global player in the radiopharmaceutical(RPT) sector within…